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Poster Session Abstracts
aeruginosa virulence factors, most likely LPS, reduce the immunogenicity
of the organism resulting in reduced activation of the type I IFN pathway, a
potential mechanism by which the pathogen evades clearance by the host.

lipocalin (NGAL) that specifically scavenge bacterial siderophores, therefore preventing bacteria from establishing infection. P. aeruginosa produces
fluorescent siderophores (pyoverdines) found to be important for biofilm
development and bacterial virulence. It is not known if P. aeruginosa strains
persisting in CF lungs evade NGAL recognition. The aim of this work is to
determine if pyoverdine binds to the antibacterial protein NGAL.
Methods: The binding of siderophores, pyoverdine from P. aeruginosa
and enterobactin from E.coli, to the recombinant NGAL protein was determined using the tryptophan fluorescence quenching method.
Results: We found that pyoverdine did not bind to NGAL either in apo
form or when complexed with iron. We used enterobactin as a control, and
as expected, enterobactin bound to NGAL causing strong tryptophan
quenching. The data indicate that the major siderophore of P. aeruginosa,
pyoverdine, evades NGAL recognition therefore dysregulating host ironlimiting innate defenses. We then investigated whether pyoverdine modulates other innate immune defenses such as respiratory burst. Upon phagocytosis of invading pathogen, respiratory burst is triggered as a defense
mechanism that leads to reactive oxygen species (ROS) release which is
important for the oxidative killing of invading pathogens. We observed that
pyoverdine decreased ROS release when added at the peak of the respiratory burst in THP-1 cells primed with P. aeruginosa LPS (10 pmol/mL) and
detected using the chemiluminescent probe lucigenin. The data suggest that
pyoverdine dampens the respiratory burst possibly by scavenging released
ROS to spare the oxidative killing of invading P. aeruginosa. Taken together, our data suggest that pyoverdine is a stealth siderophore and a virulence
factor that helps P. aeruginosa evade the ROS mediated oxidative killing.
Conclusions: P. aeruginosa persists in the CF host by evading both the
iron-limiting innate defenses and the oxidative killing by macrophages.
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VORICONAZOLE PHARMACOKINETIC PARAMETERS
IN PATIENTS WITH CYSTIC FIBROSIS
Jin, L.; Novak, K.J. Department of Pharmacy, Nationwide
Children’s Hospital, Columbus, OH, USA
Purpose: The use of voriconazole has become more prevalent over the
years to treat cystic fibrosis (CF) patients with allergic bronchopulmonary
aspergillosis (ABPA) failing itraconazole therapy or with invasive fungal
lung disease. However, voriconazole pharmacokinetic data are lacking in CF
patients, and little is known on the optimal dosage of voriconazole in pediatric patients. A small group of CF patients have undergone voriconazole
therapeutic drug monitoring over the past 6 years at our institution. The
objective of this study is to retrospectively assess whether standard doses of
intravenous and oral voriconazole yield therapeutic concentrations in CF
patients.
Methods: Electronic medical records and laboratory data were used to
identify CF patients who underwent voriconazole therapeutic drug monitoring since January 1, 2004. Patients younger than 2 years of age and who did
not have a definitive diagnosis of CF were excluded from this study. The following data were collected: patient age, gender, ethnicity, results from fungal cultures, liver function tests, IgE levels, indication for voriconazole use,
dose of voriconazole administered, duration of voriconazole therapy, and
serum level of voriconazole. Concomitant use of medications known to be
contraindicated with voriconazole use, reported adverse events associated
with use of voriconazole, and overall clinical outcome of patients were also
evaluated in this study. Doses of voriconazole used in CF patients included
in this study were compared to standard doses of voriconazole. Voriconazole
therapeutic levels were also compared to current therapeutic goals in treating ABPA and other invasive fungal lung infections.
Results: The study included 15 patients (mean age 22.3 ± 9.6, range 436, years) receiving 21 treatment courses. The most common indication for
voriconazole use was for treatment of positive respiratory fungal cultures in
post-lung transplant patients (11). Other indications included prophylaxis
for fungal infections in post-lung transplant patients (2), treatment of positive respiratory fungal cultures in non-transplant CF patients (3), empiric
coverage of respiratory fungal infections in non-transplant CF patients (3),
and treatment of ABPA (2). The mean voriconazole dose used was 207.9 ±
76.7 mg (4.8 ± 2.3 mg/kg), and the mean serum voriconazole level obtained
was 1.9 ± 1.7 mg/L. The mean voriconazole dose used in this population
was near the standard flat voriconazole dose in adult patients but at a higher mg/kg than in an average adult population. Only 57% of patients in this
study achieved a therapeutic serum voriconazole level of ≥ 1 mg/L. Two
patients had LFT increases ≥ 3 times the upper normal limit. Three patients
were on medications contraindicated with concurrent voriconazole therapy;
however, no toxicity was observed.
Conclusions: Serum voriconazole concentrations were unpredictable
in our CF population. Patients with CF may require higher than standard
voriconazole doses to yield therapeutic voriconazole levels, and therapeutic
drug monitoring may be a useful tool for individualized dosing in CF
patients.
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HOST CELL SIGNALING INDUCED BY SEQUENTIAL
ISOLATES OF PSEUDOMONAS AERUGINOSA
Cohen, T.S.1; Ernst, R.K.2; Prince, A.1 1. Columbia University,
New York, NY, USA; 2. University of Maryland-Baltimore,
Baltimore, MD, USA
Bacterial activation of the type I interferon (IFN) pathway has been
demonstrated to be important in the clearance of mucosal pathogens. In
Gram negative infections the LPS/TLR4/TRIF signaling pathway is a major
inducer of the type I IFN cascade. The immunogenicity of Pseudomonas
aeruginosa changes over the course of colonization of the CF lung due to
alterations in virulence factor expression, therefore we hypothesize that
alterations in LPS structure reduces bacterial activation of the type I IFN
cascade. Our hypothesis was tested by stimulating (4 hours) human immune
(primary dendritic cells (DC) and THP-1) cells and epithelial (BEAS-2B)
with P. aeruginosa strains isolated from single CF patients at early (3 or 5
months) and late (14 years) stages of colonization. Analysis of the strains by
random amplification of polymorphic DNA (RAPD) confirmed that early
and late isolates shared a common genetic background. Activation of NFκB
(IL-8) and IFN (IFNβ) signaling was measured by RT-PCR in DCs and
THP-1 immune cells, or luciferase reporter and ELISA in the BEAS-2B
epithelial cells. Stimulation with the early isolate induced higher levels of
NFκB signaling activation in DC (9.81 and 3.81 fold of unstimulated) and
THP-1 (5.26 and 2.62 fold of unstimulated) immune cells compared with
late isolates, however similar induction levels were observed in BEAS-2B
(6.10 and 7.89 fold of unstimulated) cells. NFκB signaling in the BEAS-2B
was confirmed by ELISA analysis of IL-8 in the supernatant of cells stimulated with early and late isolates (113.9 and 215.6 pg/mL). Induction of IFN
signaling by the early isolate was also higher than that induced by the late
isolate in DC (10.10 and 3.86 fold to unstimulated) and THP-1 (4.98 and
1.85 fold to unstimulated) cells. Interestingly, IFN signaling induction by
the early isolate was also higher in the epithelial BEAS-2B line compared to
levels induced by the late isolate (14.14 and 8 fold to unstimulated). This
data demonstrates that during colonization P. aeruginosa loses its immunostimulatory capacity in a host cell type and pathway dependent manner. To
support our hypothesis that alterations to LPS are responsible for the reduction in P. aeruginosa immunostimulatory capacity we stimulated murine
nasal epithelial cells with the different P. aeruginosa isolates. Unlike human
TLR4, activation of murine TLR4 is unaffected by alterations in LPS structure. We observed no difference in NFκB (21.73 and 22.71 fold to unstimulated) or IFN (228.1 and 278.2 fold to unstimulated) signaling by RT-PCR
in murine epithelial cells. Therefore we concluded that modifications in P.
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POPULATION PHARMACOKINETIC (PK) AND
PHARMACODYNAMIC (PD) MODELING OF
TICARCILLIN-CLAVULANATE IN PEDIATRIC CF
PATIENTS
Zobell, J.T.1,3; Stockmann, C.2,4; Young, D.C.3; Cash, J.1;
Sherwin, C.2; Spigarelli, M.2; Chatfield, B.A.2; Ampofo, K.2,4 1.
Pharmacy, Intermountain Primary Children’s Medical Center,
Salt Lake City, UT, USA; 2. Department of Pediatrics, University
of Utah, Salt Lake City, UT, USA; 3. College of Pharmacy,
University of Utah, Salt Lake City, UT, USA; 4. Division of
Infectious Diseases, University of Utah, Salt Lake City, UT, USA
Background: The Intermountain CF Pediatric Center utilizes ticarcillin-clavulanate 400 mg/kg/day div q 6 hours, (max 24 grams/day). This
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dosing strategy is higher than the FDA approved package labeling. We simulated in model the microbiological efficacy of this dosing regimen. The primary objective of this study was to use PK/PD models to estimate the likelihood of achieving bacteriostatic and bactericidal effects against a range of
P. aeruginosa minimum inhibitory concentration (MIC) values using a higher than FDA approved dose of ticarcillin-clavulanate.
Methods: This was a population-based PK/PD modeling study of pediatric CF patients admitted from 01/01/05 to 12/1/09 who received the dosing regimen for ≥7 days. Population PK and PD models were used to estimate PK and PD parameters. Serum ticarcilin concentration levels were
modeled using published PK parameters. A 10,000 patient Monte Carlo
simulation was performed to estimate the target time in which free drug concentrations exceeded the MIC of the infecting organism. The two PK/PD
MIC breakpoints used included ≥30% for bacteriostasis, and ≥50% for bactericidal effects of ticarcillin-clavulanate at higher than FDA approved
doses.
Results: A total of 127 patients met inclusion criteria. Predicted intermittent ticarcillin peak concentrations were 288±93.4 mg/L. The model predicted the probability of target attainment (PTA) of MICs for P. aeruginosa
with a near-maximal bactericidal PK-PD MIC breakpoint of 16 mcg/mL,
and a bacteriostasis PK-PD MIC breakpoint of 32 mcg/mL. (See Table.)
Conclusions: In our simulation, higher than FDA approved doses of
ticarcillin-clavulanate are effective in achieving bactericidal effects among
pseudomonal isolates with MICs below 16 mcg/mL. Bacteriostatic and bactericidal effects were not frequently achieved among P. aeruginosa isolates
with MICs above 32 mcg/mL.

baseline in FEV1 % predicted at the end of each of the 3 EXT courses were
calculated using a mixed-model repeated measures analysis.
Results: Of 174 European pts in RAND, 133 (76%) enrolled in EXT; 65
TIS-treated pts in RAND switched to AZLI in EXT (TIS/AZLI); 68 AZLItreated pts in RAND continued AZLI in EXT (AZLI/AZLI).
Mean % changes from RAND baseline in FEV1 % predicted:
At RAND week 20 after 3 treatment courses: AZLI: +7.2% vs. TIS: 2.4%
At the end of each of the 3 AZLI treatment courses in EXT: TIS/AZLI:
+3.9, +3.4 and +1.0;
AZLI/AZLI: +5.6, +3.7 and +4.2.
Body weight remained above baseline for AZLI/AZLI pts through all 6
AZLI treatment courses. TIS/AZLI pts had weight loss during RAND while
on TIS, but gained and maintained weight above baseline values after
switching to AZLI in EXT. No new safety issues were noted.
Conclusions: CF pts treated with AZLI demonstrated FEV1 improvements after each of 6 treatment courses. CF pts showed no FEV1 improvements after 3 courses of TIS but had favorable lung function responses after
switching to AZLI in EXT. In addition, AZLI but not TIS treatment was
associated with weight gain above baseline.
Supported by Gilead Sciences.
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BORDETELLA BRONCHISEPTICA IN A PEDIATRIC
CYSTIC FIBROSIS CENTER
Brady, C.1,2; Johnson, M.1; Ackerman, P.1; McNamara, J.1,2 1.
Cystic Fibrosis Research Program, Children’s Hospitals and
Clinics of Minnesota, Minneapolis, MN, USA; 2. Children’s
Respiratory and Critical Care Specialists, Minneapolis, MN, USA

Probability of target attainment (%) for ticarcillin at 30% and 50%
of the time in which free drug concentrations exceed the MIC

Background: Bordetella bronchiseptica (Bb) is a gram-negative coccobacillus typically found in domestic animals such as dogs, horses and
cats. It occurs as a commensal or pathogenic organism. In dogs, it causes an
infectious tracheobronchitis commonly known as “kennel cough.” Despite
frequent contact with domestic animals, it is rarely reported in humans and
typically occurs in immunocompromised hosts. The role of this organism as
a pathogen or colonizer is poorly understood, in part due to a challenging
and labor intensive process to isolate it. We describe isolation of Bb on
twenty-three occasions in seven children with cystic fibrosis (CF). Our experience suggests that Bb may play a potential pathogenic role in CF.
Methods: A retrospective, descriptive study was conducted of our center’s CF patient population between 1991 and 2011. The CF center currently cares for approximately 130 active patients per year. Patients were included if they had Bb isolated on one or more occasion. Patient charts were
reviewed for demographics, CF diagnosis, lung function, nutritional status
and exposure to domestic animals. In addition, data on previous or concurrent airway cultures, organism sensitivities, signs and symptoms of pulmonary exacerbations, hospitalizations, treatment, and response to therapy
one year before and after first Bb isolation were reviewed.
Results: Seven patients (female N=5) between ages 1-20 with CF had
Bb isolated in airway cultures on 23 occasions. Of these, four patients grew
Bb once and three on multiple occasions. All patients had one copy of the
∆F508 mutation and four were homozygous ∆F508. On one occasion, Bb
was initially identified as an organism called CDC-IVc-2, which is a short to
medium rod that closely resembles Bb. Six patients experienced increased
cough within one month prior to first isolation, and four had additional pulmonary symptoms. Four patients required hospitalization. All patients isolated methicillin-sensitive Staphylococcus aureus (MSSA) either historically or concurrently with Bb. None of our patients were colonized with
Pseudomonas aeruginosa mucoid although two patients isolated
Pseudomonas aeruginosa matte intermittently. All patients had documented
contact with domestic animals. Two patients were exposed to animals with
a veterinarian-diagnosed case of “kennel cough.”
Conclusion: As successful targeted therapies improve the care of
patients colonized with Pseudomonas aeruginosa, other potential pathogens
have emerged. While its significance as a respiratory pathogen is unclear,
our experience suggests Bb may act as a pathogenic organism in CF. Laboratory isolation and identification of Bb can be challenging, suggesting that
it may be more common than previously reported. Close laboratory scrutiny of unusual isolates in culture is recommended. In addition, we suggest
routine environmental history to include contact with and immunization of
domestic animals that potentially carry Bb.
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LUNG FUNCTION IMPROVEMENT WITH AZTREONAM
FOR INHALATION SOLUTION (AZLI) IN THE SINGLEARM EXTENSION OF A RANDOMIZED TRIAL OF
INHALED ANTIPSEUDOMONAL ANTIBIOTICS IN
PATIENTS WITH CYSTIC FIBROSIS (CF) AND
PSEUDOMONAS AERUGINOSA INFECTION
Assael, B.M.1; Chiron, R.2; Fischer, R.3; Bresnik, M.4; Lewis, S.5;
Pressler, T.6; Oermann, C.M.7 1. CF Center, Verona, Italy; 2.
CHU de Montpellier, Montpellier, France; 3. University of
Munich, Munich, Germany; 4. Gilead Sciences, Foster City, CA,
USA; 5. Gilead Sciences, Seattle, WA, USA; 6. National
University Hospital, Copenhagen, Denmark; 7. Baylor College of
Medicine, Houston, TX, USA
Objectives: In a 6 month randomized, active comparator trial of three
28-day on/off courses of AZLI (Cayston®, Gilead Sciences) vs. tobramycin
inhalation solution (TIS) in 268 CF patients (pts) with chronic Pseudomonas
aeruginosa (PA) infection, AZLI was superior to TIS at 28 days and over 3
treatment courses in lung function (FEV1) improvements. A single-arm
extension phase (EXT) of this study evaluated the safety and efficacy of
AZLI for 3 additional 28-day on/off treatment cycles (ClinicalTrials.gov
NCT00757237).
Methods: CF pts ≥6 yrs old with chronic PA infection, baseline FEV1
≤75% predicted, and stable pulmonary disease were enrolled in the randomized, active comparator phase of the trial (RAND). EXT was open to European pts completing ≥1 course of AZLI or TIS during RAND. Pts were off
antibiotics for 14-28 days prior to starting RAND. All pts in EXT received
AZLI 75 mg TID via the Pari Investigational eFlow® Nebulizer System for
3 treatment courses (28 days on/28 days off). Mean % changes from RAND
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